MedTrace Logo

Gut Microbiome in DLBCL Treated With Glofitamab

NCT07498920 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-03-27

No results posted yet for this study

Summary

The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.

Conditions

  • DLBCL
  • Glofitamab
  • Gut Biome

Interventions

OTHER

Gut microbiome analysis

Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2029-04-01
Completion
2029-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07498920 on ClinicalTrials.gov